NIMGENETICS GENOMICA Y MEDICINA, S.L, a Portfolio Company of Apposite Capital, has Completed

the Acquisition of GENE PREDICTIS, S.A.

NIMGenetics Genomica y Medicina, S.L. ("NIM") is pleased to announce that it completed the acquisition of Gene Predictis, S.A. ("GP"), a Swiss-based medical diagnostic company, and leader in

the field of preventive health and precision medicine.

Since its foundation in 2004, Gene Predictis has created a unique expertise in developing polygenic

and multifactorial risk scores for interpreting complex genetic data.

This acquisition reinforces NIM's firm intent to its international expansion, with a focus on Central European markets, and bring additional verticals such as pharmacogenetics, microbiology, and

infectious diseases. The synergies and customer growth for both companies will place NIM at the

forefront of the genetic diagnostics market in Europe.

Enrique Samper, co-founder, and CEO of NIM, said that "this acquisition will boost our expansion in

Europe and usher in a new phase of development marked by future strategic alliances".

Gene Predictis CEO, Goranka Tanackovic, describes the integration into the group as "a great

opportunity to expand our activity internationally, and to focus on our main areas of expertise".

Anne-Laure Meynier, Investment Director at Apposite Capital added: "We are delighted that NIM has completed this acquisition. This demonstrates that NIM is an attractive platform for market

consolidation, adding partner firms – aligned with our high-quality products and service delivery – to

the group, supporting rapid growth of local provision."

 $NIM\ is\ a\ science-lead\ genetic\ diagnostic\ company,\ developing\ and\ distributing\ genetic\ diagnostic\ tests,$

reagents and associated software and is present in Spain & Portugal, Brazil and Mexico, serving

customers globally.

Advice and support to NIM was provided by BDO, Pinsent and BAT Law. Advice and support to GP was

provided by Kellerhals Carrard.

[Ends]

Media contact:

Goranka Tanackovic

Tel: +41 (0) 21 691 43 75

Email: gat@genepredictis.com

About Apposite Capital

www.appositecapital.com

Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life

sciences, and digital health.

Apposite Capital operates at the small end of the private equity market, providing both capital and

expertise to those businesses offering 'disruptive' models that aim to improve or reduce the cost of

care provision and which have the potential to become market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies both organically and inorganically.

Apposite Capital was established in 2006 and is headquartered in London, UK.

About NIMGenetics

www.nimgenetics.com

NIMGenetics is a Spanish multinational biotech specialised in the design and commercialisation of clinical genetic diagnosis products and services, that supports specialists at all stages of the diagnostic process. Its cutting-edge diagnostic services include, among others, TrisoNIM™, a fetal DNA test, ExoNIM™, a platform for whole exome sequencing, and GenoNIM™, a comprehensive tool for genome sequencing. In addition to Spain, NIMGenetics is currently present in Portugal, Mexico and Brazil, serving customers worldwide.

About Gene Predictis

www.genepredictis.com

Gene Predictis has a long track record in the interpretation of complex genetic data, with proprietary algorithms, as well as in the development of clinical diagnostic tools in the field of preventive genetics and pharmacogenomics. It also has state-of-the-art disruptive technologies, as well as a broad portfolio of services in the areas of genetics, microbiology, and epidemiology.